Second-line treatment for adult-onset Still's disease
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests two new biologic medicines (goflikicept and olokizumab) as a second treatment option for people with adult-onset Still's disease. These drugs target inflammation to help control symptoms like fever, rash, and joint pain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with adult-onset Still's disease (AOSD), a rare type of inflammatory arthritis.
- Your disease is currently active or has low activity, meaning you have symptoms like fever, rash, or joint pain.
- If you take steroids, anti-inflammatory drugs, or methotrexate, your dose must be steady for at least 2 to 4 weeks before starting.
- You cannot have recently used certain other biologic medications (like canakinumab, tocilizumab, or anakinra) within a specific time frame.
- You must not have an active infection, tuberculosis, or a weakened immune system.
- You must agree to use effective birth control during the study and for 8 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects health information from people with adult-onset Still's disease and similar autoinflammatory conditions to better understand these diseases. By joining, you contribute to research that may lead to better care in the future.
This is a long-term study that collects health information and lab samples from people who have certain diagnoses of recurring (coming and going) inflammatory fevers and related joint or immune conditions. It may help researchers better understand these diseases and how they work over time.
This is a study looking back at patients who were already treated with a medicine called canakinumab for familial Mediterranean fever or Still's disease (rare conditions that cause fevers and joint pain). Researchers want to understand how well this medicine worked over time and what happened to patients who took it.
This trial tests a new drug called MAS825 for people with Still's disease that is still active despite other treatments. It aims to see if the drug can reduce symptoms like fever, rash, joint pain, or a serious complication called macrophage activation syndrome.
This study aims to learn more about the causes and genetics of two related inflammatory conditions: systemic juvenile idiopathic arthritis (sJIA) in children and adult-onset Still's disease (AOSD) in adults. By studying patients and healthy volunteers, researchers hope to understand these diseases better and find better ways to treat them.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
Hear when a new Still Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.